Engineering and crystal structure of a monomeric FLT3 ligand variant

被引:2
|
作者
Pannecoucke, Erwin [1 ,2 ]
Raes, Laurens [1 ,3 ]
Savvides, Savvas N. [1 ,2 ]
机构
[1] Univ Ghent, Dept Biochem & Microbiol, Unit Struct Biol, Technologiepk Zwijnaarde 71, B-9052 Zwijnaarde, Belgium
[2] VIB Ctr Inflammat Res, Unit Struct Biol, Technologiepk Zwijnaarde 71, B-9052 Zwijnaarde, Belgium
[3] Univ Ghent, Lab Gen Biochem & Phys Pharm, Ottergemsesteenweg 460, B-9000 Ghent, Belgium
来源
ACTA CRYSTALLOGRAPHICA SECTION F-STRUCTURAL BIOLOGY COMMUNICATIONS | 2021年 / 77卷
关键词
FLT3; ligand; receptor tyrosine kinases; acute myeloid leukemia; ACUTE MYELOID-LEUKEMIA; RECEPTOR; ACTIVATION; EFFICIENT; KIT;
D O I
10.1107/S2053230X21003289
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
The overarching paradigm for the activation of class III and V receptor tyrosine kinases (RTKs) prescribes cytokine-mediated dimerization of the receptor ectodomains and homotypic receptor-receptor interactions. However, structural studies have shown that the hematopoietic receptor FLT3, a class III RTK, does not appear to engage in such receptor-receptor contacts, despite its efficient dimerization by dimeric FLT3 ligand (FL). As part of efforts to better understand the intricacies of FLT3 activation, we sought to engineer a monomeric FL. It was found that a Leu27Asp substitution at the dimer interface of the cytokine led to a stable monomeric cytokine (FLL27D) without abrogation of receptor binding. The crystal structure of FLL27D at 1.65 angstrom resolution revealed that the introduced point mutation led to shielding of the hydrophobic footprint of the dimerization interface in wild-type FL without affecting the conformation of the FLT3 binding site. Thus, FLL27D can serve as a monomeric FL variant to further interrogate the assembly mechanism of extracellular complexes of FLT3 in physiology and disease.
引用
收藏
页码:121 / 127
页数:7
相关论文
共 50 条
  • [1] Further activation of FLT3 mutants by FLT3 ligand
    R Zheng
    E Bailey
    B Nguyen
    X Yang
    O Piloto
    M Levis
    D Small
    Oncogene, 2011, 30 : 4004 - 4014
  • [2] Further activation of FLT3 mutants by FLT3 ligand
    Zheng, R.
    Bailey, E.
    Nguyen, B.
    Yang, X.
    Piloto, O.
    Levis, M.
    Small, D.
    ONCOGENE, 2011, 30 (38) : 4004 - 4014
  • [3] MECHANISM OF FLT3 LIGAND DEPENDENT RESISTANCE TO FLT3 INHIBITORS
    Chen, Fangli
    Ishikawa, Yuichi
    Kihara, Rika
    Naoe, Tomoki
    Kiyoi, Hitoshi
    EXPERIMENTAL HEMATOLOGY, 2015, 43 (09) : S57 - S57
  • [4] FLT3: Receptor and ligand
    Drexler, HG
    Quentmeier, H
    GROWTH FACTORS, 2004, 22 (02) : 71 - 73
  • [5] Mechanism of FLT3 Ligand Dependent Resistance to FLT3 Inhibitors
    Chen, Fangli
    Ishikawa, Yuichi
    Kiyoi, Hitoshi
    Naoe, Tomoki
    BLOOD, 2014, 124 (21)
  • [6] FLT3 ligand impedes the efficacy of FLT3 inhibitors in vitro and in vivo
    Sato, Takashi
    Yang, Xiaochuan
    Knapper, Steven
    White, Paul
    Smith, B. Douglas
    Galkin, Steven
    Small, Donald
    Burnett, Alan
    Levis, Mark
    BLOOD, 2011, 117 (12) : 3286 - 3293
  • [7] Expression of FLT3 receptor and response to FLT3 ligand by leukemic cells
    Drexler, HG
    LEUKEMIA, 1996, 10 (04) : 588 - 599
  • [8] FLT3 mutant activation is still dependent on FLT3 ligand.
    Zheng, R
    Piloto, O
    Small, D
    BLOOD, 2005, 106 (11) : 646A - 646A
  • [9] FLT3 ligand is required for full activation of FLT3 mutants.
    Zheng, Rui
    Piloto, Obdulio
    Small, Donald
    BLOOD, 2006, 108 (11) : 186A - 186A
  • [10] Structure function studies of human FLT3 ligand.
    Escobar, S
    Brasel, K
    Anderberg, R
    Lyman, SD
    BLOOD, 1995, 86 (10) : 74 - 74